摘要
目的探讨海昆肾喜胶囊联合复方α-酮酸片治疗慢性肾功能衰竭的临床效果。方法选取2016月3月-2019年4月天津市第一中心医院收治的90例慢性肾功能衰竭患者,随机分为对照组和治疗组,每组各45例。对照组口服复方α-酮酸片,4片/次,3次/d,用餐期间整片吞服。治疗组在对照组基础上口服海昆肾喜胶囊,2粒/次,3次/d。两组均连续治疗2个月。观察两组的临床疗效,比较两组治疗前后肾功能指标、EQ-5D评分、血清学指标的变化情况。结果治疗后,对照组和治疗组的总有效率分别是82.2%、95.6%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清肌酐(Cr)、尿素氮(BUN)水平均显著降低,而内生肌酐清除率(Ccr)和白蛋白(ALB)均显著高于治疗前,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组血清Cr、BUN水平低于对照组,而Ccr值和ALB高于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组EQ-5D健康效用值、EQ-VAS评分均较治疗前显著升高,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组EQ-5D健康效用值、EQ-VAS评分高于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组血清白介素(IL)-8、脂质过氧化物(LPO)及C-反应蛋白(CRP)水平均显著下降,而谷胱甘肽过氧化物酶(GSH-Px)水平均显著增高,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组IL-8、LPO及CRP水平显著低于对照组,而GSH-Px水平高于对照组,两组比较差异有统计学意义(P<0.05)。结论海昆肾喜胶囊联合复方α-酮酸治疗慢性肾功能衰竭的整体疗效显著,能有效改善患者肾功能,抑制机体炎性反应和氧化应激,提高患者生命质量,具有一定的临床推广应用价值。
Objective To investigate the clinical effect of Haikun Shenxi capsules combined with Compound α-Ketoacid Tablets in treatment of chronic renal failure. Methods Patients(90 cases) with chronic renal failure in Tianjin First Central Hospital from March 2016 to April 2019 were randomly divided into control(45 cases) and treatment(45 cases) groups. Patients in the control group were po administered with Compound α-Ketoacid Tablets swallow whole during meals, 4 tablets/time, three times daily. Patients in the treatment group were po administered with Haikun Shenxi Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the changes of renal function indexes, EQ-5 D score and serological indexes before and after treatment in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 82.2% and 95.6%, respectively, and there were differences between two groups(P < 0.05). After treatment, Cr and BUN in two groups were significantly decreased, but Ccr and ALB were significantly increased, and there were differences in the same group(P < 0.05). After treatment, Cr and BUN in the treatment group were lower than those in the control group, but Ccr and ALB were higher than those in the control group, and there were differences between two groups(P < 0.05). After treatment, EQ-5 D health utility value and EQ-VAS score were significantly increased, and there were differences in the same group(P < 0.05). After treatment, EQ-5 D health utility value and EQ-VAS score in the treatment group were higher than those in the control group, and there were differences between two groups(P < 0.05). After treatment, IL-8, LPO, and CRP in two groups were significantly decreased, but GSH-Px was significantly increased, and there were differences in the same group(P < 0.05). After treatment, IL-8, LPO, and CRP in the treatment group were lower than those in the
作者
丁宏
韩鹦赢
张弋
DING Hong;HAN Ying-ying;ZHANG Yi(Department of Pharmacy,Tianjin First Central Hospital,Tianjin 300192,China;Department of Nephrology,Tianjin First Central Hospital,Tianjin 300192,China)
出处
《现代药物与临床》
CAS
2019年第10期3050-3054,共5页
Drugs & Clinic
